{"title":"Drug discovery targeting thyroid hormone receptor β (THRβ) for the treatment of liver diseases and other medical indications","authors":"Kean Wang, Feiyang Chen, Jiang Wang, Hong Liu","doi":"10.1016/j.apsb.2024.07.025","DOIUrl":null,"url":null,"abstract":"Thyroid hormone receptors (THRs), a crucial nuclear receptor protein family, primarily consist of two categories: receptors and receptors. Among them, THR is the primary subtype of thyroid hormone that confers benefits to the liver. In the last two decades, there have been efforts to develop THR agonists that selectively yield beneficial effects on the liver, such as lowering triglycerides and cholesterol, while reducing adverse effects on the heart, muscle, and bone. This paper systematically reviews strategies to enhance the safety of THR agonists for the treatment of MASH, with a focus on improving the selectivity of THR and increasing the distribution of the drug in the liver. Additionally, we explore the potential application of this target in addressing other medical indications.","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"49 1","pages":""},"PeriodicalIF":14.7000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica Sinica. B","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/j.apsb.2024.07.025","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Thyroid hormone receptors (THRs), a crucial nuclear receptor protein family, primarily consist of two categories: receptors and receptors. Among them, THR is the primary subtype of thyroid hormone that confers benefits to the liver. In the last two decades, there have been efforts to develop THR agonists that selectively yield beneficial effects on the liver, such as lowering triglycerides and cholesterol, while reducing adverse effects on the heart, muscle, and bone. This paper systematically reviews strategies to enhance the safety of THR agonists for the treatment of MASH, with a focus on improving the selectivity of THR and increasing the distribution of the drug in the liver. Additionally, we explore the potential application of this target in addressing other medical indications.
Acta Pharmaceutica Sinica. BPharmacology, Toxicology and Pharmaceutics-General Pharmacology, Toxicology and Pharmaceutics
CiteScore
22.40
自引率
5.50%
发文量
1051
审稿时长
19 weeks
期刊介绍:
The Journal of the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association oversees the peer review process for Acta Pharmaceutica Sinica. B (APSB).
Published monthly in English, APSB is dedicated to disseminating significant original research articles, rapid communications, and high-quality reviews that highlight recent advances across various pharmaceutical sciences domains. These encompass pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis, and pharmacokinetics.
A part of the Acta Pharmaceutica Sinica series, established in 1953 and indexed in prominent databases like Chemical Abstracts, Index Medicus, SciFinder Scholar, Biological Abstracts, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, and Current Bibliography on Science and Technology, APSB is sponsored by the Institute of Materia Medica, Chinese Academy of Medical Sciences, and the Chinese Pharmaceutical Association. Its production and hosting are facilitated by Elsevier B.V. This collaborative effort ensures APSB's commitment to delivering valuable contributions to the pharmaceutical sciences community.